Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions Between Tyrosine Kinase Inhibitors and Cardiovascular Drugs [version 2; peer review: 2 approved, 1 approved with reservations]

Background As lung cancer treatment has progressed, there has been an increase in awareness of the short- and long-term adverse effects of targeted cancer therapies of tyrosine kinase inhibitors, particularly cardiovascular toxicities. Methods The current study assessed the potential drug-drug inter...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Mrunal Desai, Prajakta Patil, Sumit Birangal, Mahadev Rao, Jagadish P. C., Gurupur Gautham Shenoy, Viswam Subeesh, Levin Thomas, Gayathri Baburaj
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	F1000 Research Ltd 2025-10-01
Ráidu:	F1000Research
Fáttát:	Cardiovascular drugs Drug-drug interactions NSCLC IBM Micromedex Drugs.com Molecular docking eng
Liŋkkat:	https://f1000research.com/articles/14-309/v2
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!